Treatment in rapid eye-movement sleep behavior disorder

doi:10.3877/cma.j.issn.2095-8757.2020.01.010

Abstract

Abstract:

Rapid eye movement sleep behavior disorder (RBD) is a common type of sleep disorder in the elderly, which is characterized by complex dreams and violent behaviors during the deep sleep. It is a precursor marker of a variety of synuclein diseases, such as Parkinson's disease, multiple system atrophy and so on. The current pathogenesis of RBD is not fully understood, and there is no final conclusion on the therapeutic effect of the drug therapy. This article will focus on the review of drug and non drug treatment of RBD, in order to provide basis for clinical prevention and treatment of synuclein disease..

Key words: Rapid eye-movement sleep behavior disorder, Treatment, Sleep disorder, Neuroprotection

Hong Wang, Chen Hou, Rui Li, Peng Tang. Treatment in rapid eye-movement sleep behavior disorder[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2020, 07(01): 41-46.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2020.01.010

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2020/V07/I01/41

References 62

[1]	Frauscher B, Gschliesser V, Brandauer E, et al. Video analysis of motor events in REM sleep behavior disorder[J]. Mov Disord, 2007, 22(10):1464-7140.
[2]	Wing YK, Lam SP, Li SX, et al. REM sleep behaviour disorder in Hong Kong Chinese: clinical outcome and gender comparison[J]. J Neurol Neurosurg Psychiatry, 2008, 79(12):1415-1416.
[3]	Zhang J, Lam SP, Ho CK, et al. Diagnosis of REM sleep behavior disorder by video-polysomnographic study: is one night enough[J]? Sleep, 2008, 31(8):1179-1185.
[4]	Iranzo A, Santamaria J, Tolosa E. Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions[J]. Lancet Neurology, 2016, 15(4):405-419.
[5]	Wichniak A, Wierzbicka A, Walecka M, et al. Effects of Antidepressants on Sleep[J]. Curr Psychiatry Rep, 2017, 19(9):63.
[6]	Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications[J]. Chest, 2014, 146(5):1387-1394.
[7]	Pujol M, Pujol J, Alonso T, et al. Idiopathic REM sleep behavior disorder in the elderly Spanish community: a primary care center study with a two-stage design using video-polysomnography[J]. Sleep Med, 2017, 40:116-121.
[8]	Rodriguez CL, Jaimchariyatam N, Budur K. Rapid eye movement sleep behavior disorder: A review of the literature and update on current concepts[J]. Chest, 2017, 152(3):650-662.
[9]	Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP[J]. Sleep, 2002, 25(2):120-138.
[10]	Haba-Rubio J, Frauscher B, Marques-Vidal P, et al. Prevalence and determinants of REM sleep behavior disorder in the general population[J].Sleep, 2018, 41(2). doi: 10.1093/sleep/zsx197.
[11]	Galbiati A, Verga L, Giora E, et al. The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies[J]. Sleep Med Rev, 2019, 43:37-46.
[12]	Iranzo A, Santamaria J, Valldeoriola F, et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder[J]. Ann Neurol, 2017, 82(3):419-428.
[13]	Postuma RB, Gagnon JF, Vendette M, et al. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder[J]. Ann Neurol, 2011, 69(5):811-818.
[14]	Sasai T, Matsuura M, Inoue Y. Electroencephalographic findings related with mild cognitive impairment in idiopathic rapid eye movement sleep behavior disorder[J]. Sleep, 2013, 36(12):1893-1899.
[15]	Genier Marchand D, Montplaisir J, Postuma RB, et al. Detecting the cognitive prodrome of dementia with lewy bodies: A prospective study of rem sleep behavior disorder[J]. Sleep, 2017, 40(1). doi: 10.1093/sleep/zsw014.
[16]	Youn S, Kim T, Yoon IY, et al. Progression of cognitive impairments in idiopathic REM sleep behaviour disorder[J]. J Neurol Neurosurg Psychiatry, 2016, 87(8):890-896.
[17]	Ferini-Strambi L, Marelli S, Galbiati A, et al. REM Sleep Behavior Disorder (RBD) as a marker of neurodegenerative disorders[J]. Arch Ital Biol, 2014, 152(2-3):129-146.
[18]	中华医学会神经病学分会睡眠障碍学组.中国快速眼球运动睡眠期行为障碍诊断与治疗专家共识[J].中华神经科杂志，2017，50(8):567-571.
[19]	Kunz D, Bes F. Twenty years after: another case report of melatonin effects on REM sleep behavior disorder, using serial dopamine transporter imaging[J]. Neuropsychobiology, 2017, 76(2):100-104.
[20]	Schenck CH, Bundlie SR, Ettinger MG, et al. Chronic behavioral disorders of human REM sleep: A new category of parasomnia[J]. Sleep, 1986, 9(2):293-308.
[21]	Lapierre O, Montplaisir J. Polysomnographic features of REM sleep behavior disorder: development of a scoring method[J]. Neurology, 1992, 42(7):1371-1374.
[22]	Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases[J]. Brain, 2000, 123(Pt 2):331-339.
[23]	Hendricks JC, Lager A, O'Brien D, et al. Movement disorders during sleep in cats and dogs[J]. J Am Vet Med Assoc, 1989, 194(5):686-689.
[24]	Shin C, Park H, Lee WW, et al. Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial[J]. J Neurol Sci, 2019, 401:81-86.
[25]	Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam[J]. J Clin Sleep Med, 2009, 5(3):235-239.
[26]	McCarter SJ, Boswell CL, St Louis EK, et al. Treatment outcomes in REM sleep behavior disorder[J]. Sleep Med, 2013, 14(3):237-242.
[27]	Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease[J]. Brain, 2007, 130(Pt 11):2770-2788.
[28]	Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD)[J]. J Clin Sleep Med, 2010, 6(1):85-95.
[29]	Griebling TL. Re: American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults[J]. J Urol, 2019, 202(3):438.
[30]	Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism[J]. Clin Pharmacokinet, 2002, 41(12):913-958.
[31]	St Louis EK. Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects[J]. Curr Neuropharmacol, 2009, 7(2):96-105.
[32]	Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition[J]. Clin Pharmacokinet, 2000, 38(1):41-57.
[33]	Brzezinski A. Melatonin in humans[J]. N Engl J Med, 1997, 336(3):186-195.
[34]	Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder[J]. J Sleep Res, 2010, 19(4):591-596.
[35]	Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation[J]. Mov Disord, 1999, 14(3):507-511.
[36]	Takeuchi N, Uchimura N, Hashizume Y, et al. Melatonin therapy for REM sleep behavior disorder[J]. Psychiatry Clin Neurosci, 2001, 55(3):267-269.
[37]	Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients[J]. Sleep Med, 2003, 4(4):281-284.
[38]	Kunz D. Melatonin in rapid eye movement sleep behavior disorder: why does it work[J]? Sleep Med, 2013, 14(8):705-706.
[39]	Kunz D, Mahlberg R, Muller C, et al. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials[J]. J Clin Endocrinol Metab, 2004, 89(1):128-134.
[40]	Attenburrow ME, Cowen PJ, Sharpley AL. Low dose melatonin improves sleep in healthy middle-aged subjects[J]. Psychopharmacology (Berl), 1996, 126(2):179-181.
[41]	McGrane IR, Leung JG, St Louis EK, et al. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence[J]. Sleep Med, 2015, 16(1):19-26.
[42]	Arnaldi D, Antelmi E, St Louis EK, et al. Idiopathic REM sleep behavior disorder and neurodegenerative risk: To tell or not to tell to the patient? How to minimize the risk[J]? Sleep Med Rev, 2017, 36:82-95.
[43]	Seabra ML, Bignotto M, Pinto LR, et al. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment[J]. J Pineal Res, 2000, 29(4):193-200.
[44]	San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system[J]. Eur Psychiatry, 2008, 23(6):396-402.
[45]	Bonakis A, Economou NT, Papageorgiou SG, et al. Agomelatine may improve REM sleep behavior disorder symptoms[J]. J Clin Psychopharmacol, 2012, 32(5):732-734.
[46]	Shiromani PJ, Gillin JC, Henriksen SJ. Acetylcholine and the regulation of REM sleep: basic mechanisms and clinical implications for affective illness and narcolepsy[J]. Annu Rev Pharmacol Toxicol, 1987, 27:137-156.
[47]	Esaki Y, Kitajima T, Koike S, et al. An open-labeled trial of ramelteon in idiopathic rapid eye movement sleep behavior disorder[J]. J Clin Sleep Med, 2016, 12(5):689-693.
[48]	Di Giacopo R, Fasano A, Quaranta D, et al. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease[J]. Mov Disord, 2012, 27(4):559-561.
[49]	Wang Y, Yang Y, Wu H, et al. Effects of rotigotine on REM sleep behavior disorder in Parkinson disease[J]. J Clin Sleep Med, 2016, 12(10):1403-1409.
[50]	Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases[J]. Neurology, 2000, 55(6):870-871.
[51]	Yeh SB, Yeh PY, Schenck CH. Rivastigmine-induced REM sleep behavior disorder (RBD) in a 88-year-old man with Alzheimer's disease[J]. J Clin Sleep Med, 2010, 6(2):192-195.
[52]	Sasai T, Matsuura M, Inoue Y. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder[J]. Parkinsonism Relat Disord, 2013,19(2):153-157.
[53]	Schmidt MH, Koshal VB, Schmidt HS. Use of pramipexole in REM sleep behavior disorder: results from a case series[J]. Sleep Med, 2006, 7(5):418-423.
[54]	Kumru H, Iranzo A, Carrasco E, et al. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease[J]. Sleep, 2008, 31(10):1418-1421.
[55]	Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease[J]. CNS Drugs, 2010, 24(11):941-968.
[56]	Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis[J]. Drug Saf, 2003, 26(6):439-444.
[57]	Tan SM, Wan YM. Pramipexole in the treatment of REM sleep behaviour disorder: A critical review[J]. Psychiatry Res, 2016, 243:365-372.
[58]	Chagas MH, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series[J]. J Clin Pharm Ther, 2014, 39(5):564-566.
[59]	Kozela E, Juknat A, Vogel Z. Modulation of astrocyte activity by cannabidiol, a nonpsychoactive cannabinoid[J]. Int J Mol Sci, 2017, 18(8). doi: 10.3390/ijms18081669.
[60]	Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort[J]. Sleep Med, 2011, 12(5):445-453.
[61]	Li SX, Wing YK, Lam SP, et al. Validation of a new REM sleep behavior disorder questionnaire (RBDQ-HK)[J]. Sleep Med, 2010, 11(1):43-48.
[62]	Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease[J]. JAMA Neurol, 2015, 72(6):707-712.

Please choose a citation manager

Content to export